(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.99% HKD 40.95
Live Chart Being Loaded With Signals
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally...
Stats | |
---|---|
Dagens volum | 80 100.00 |
Gjennomsnittsvolum | 140 298 |
Markedsverdi | 15.11B |
EPS | HKD0 ( 2023-10-25 ) |
Last Dividend | HKD0.441 ( 2023-07-04 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 15.51 |
ATR14 | HKD0.0670 (0.16%) |
Volum Korrelasjon
Shanghai Haohai Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Shanghai Haohai Korrelasjon - Valuta/Råvare
Shanghai Haohai Økonomi
Annual | 2023 |
Omsetning: | HKD2.63B |
Bruttogevinst: | HKD1.85B (70.34 %) |
EPS: | HKD2.44 |
FY | 2023 |
Omsetning: | HKD2.63B |
Bruttogevinst: | HKD1.85B (70.34 %) |
EPS: | HKD2.44 |
FY | 2022 |
Omsetning: | HKD2.10B |
Bruttogevinst: | HKD1.45B (68.79 %) |
EPS: | HKD1.040 |
FY | 2021 |
Omsetning: | HKD1.75B |
Bruttogevinst: | HKD1.26B (71.98 %) |
EPS: | HKD2.16 |
Financial Reports:
No articles found.
Shanghai Haohai Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.820 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.441 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.472 | 2016-06-08 |
Last Dividend | HKD0.441 | 2023-07-04 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD4.88 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.29 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.45 | |
Div. Directional Score | 9.03 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3989.HK | Ex Dividend Junior | 2023-07-07 | Sporadic | 0 | 0.00% | |
1795.HK | Ex Dividend Junior | 2023-06-30 | Annually | 0 | 0.00% | |
0830.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
2380.HK | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
1361.HK | Ex Dividend Knight | 2023-08-28 | Annually | 0 | 0.00% | |
0423.HK | Ex Dividend Junior | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
6808.HK | Ex Dividend Junior | 2023-08-22 | Annually | 0 | 0.00% | |
1913.HK | Ex Dividend Junior | 2023-05-03 | Annually | 0 | 0.00% | |
0945.HK | Ex Dividend King | 2023-08-22 | Quarterly | 0 | 0.00% | |
0071.HK | Ex Dividend Knight | 2023-09-25 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.158 | 1.500 | 6.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0586 | 1.200 | 8.05 | 9.66 | [0 - 0.3] |
returnOnEquityTTM | 0.0731 | 1.500 | -0.299 | -0.449 | [0.1 - 1] |
payoutRatioTTM | 0.00486 | -1.000 | 9.95 | -9.95 | [0 - 1] |
currentRatioTTM | 5.24 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.47 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.83 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0574 | -1.500 | 9.04 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 126.75 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.72 | 2.00 | 8.76 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.15 | 2.00 | 8.92 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0722 | -1.500 | 9.71 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.703 | 1.000 | 1.609 | 1.609 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.174 | 1.000 | 8.51 | 8.51 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.555 | 1.000 | 2.47 | 2.47 | [0.2 - 2] |
assetTurnoverTTM | 0.371 | 0.800 | -0.861 | -0.689 | [0.5 - 2] |
Total Score | 11.61 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 15.54 | 1.000 | 8.53 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0731 | 2.50 | -0.192 | -0.449 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.15 | 2.00 | 9.28 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.164 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.72 | 2.00 | 8.76 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.00486 | 1.500 | 9.95 | -9.95 | [0 - 1] |
pegRatioTTM | 0.764 | 1.500 | 8.24 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.241 | 1.000 | 6.48 | 0 | [0.1 - 0.5] |
Total Score | 6.45 |
Shanghai Haohai
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.